Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

SMARCA4 inhibitor

DRUG CLASS:

SMARCA4 inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

Chr t(4;14)	Multiple Myeloma	Chr t(4;14)	Multiple Myeloma	PFI-3 Sensitive: D – Preclinical PFI-3 Sensitive : D	PFI-3 Sensitive: D – Preclinical PFI-3 Sensitive : D
MLL rearrangement + FLT3 mutation	Acute Myelogenous Leukemia	MLL rearrangement + FLT3 mutation	Acute Myelogenous Leukemia	FHD-286 Sensitive: D – Preclinical FHD-286 Sensitive : D	FHD-286 Sensitive: D – Preclinical FHD-286 Sensitive : D
FLT3-ITD mutation + NPM1 mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation + NPM1 mutation	Acute Myelogenous Leukemia	revumenib + FHD-286 Sensitive: D – Preclinical revumenib + FHD-286 Sensitive : D	revumenib + FHD-286 Sensitive: D – Preclinical revumenib + FHD-286 Sensitive : D
FLT3-ITD mutation + NPM1 mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation + NPM1 mutation	Acute Myelogenous Leukemia	OTX015 + FHD-286 Sensitive: D – Preclinical OTX015 + FHD-286 Sensitive : D	OTX015 + FHD-286 Sensitive: D – Preclinical OTX015 + FHD-286 Sensitive : D